New psoriasis pill shows promise in early safety trial
NCT ID NCT05725057
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either AX-158 or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to see if the drug is safe and tolerable, with some early checks on whether it improves skin symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AX-158
What this could lead to
If it works, this could point toward a new oral treatment option for mild to moderate psoriasis.
What could go wrong
This is a small, early-phase proof-of-concept study with only 31 participants. It focuses on safety, not yet on effectiveness, so results may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accellacare North London
Northwood, United Kingdom
-
Accellacare Northamptonshire
Corby, United Kingdom
-
Accellacare South London
Orpington, United Kingdom
-
Accellacare Warwickshire
Coventry, United Kingdom
-
Accellacare Yorkshire
Shipley, United Kingdom
-
MEU
Manchester, United Kingdom